Summary: Cigna Healthcare modified its molecular and proteomic diagnostic testing coverage policy for hematology and oncology indications (Policy 0520), effective April 11, 2026. Here's what billing teams need to do.
Cigna Healthcare updated Policy 0520 — its coverage policy governing molecular and proteomic diagnostic testing for hematology and oncology — with an effective date of April 11, 2026. This policy governs tumor profiling, biomarker testing, and related molecular diagnostics billed to Cigna for cancer patients. The policy does not publish specific CPT or HCPCS codes in the version captured here, but the scope covers a category of testing that generates high-dollar claims and frequent claim denial activity. If your practice bills molecular diagnostics for oncology patients with Cigna coverage, this update deserves your attention before April 11.
| Field | Detail |
|---|---|
| Payer | Cigna Healthcare |
| Policy | Molecular and Proteomic Diagnostic Testing for Hematology and Oncology Indications |
| Policy Code | 0520 |
| Change Type | Modified |
| Effective Date | April 11, 2026 |
| Impact Level | High |
| Specialties Affected | Medical oncology, hematology, pathology, laboratory medicine, genetic counseling |
| Key Action | Review prior authorization requirements and medical necessity documentation for all molecular and proteomic oncology tests billed to Cigna before April 11, 2026 |
Cigna Molecular and Proteomic Oncology Testing Coverage Criteria and Medical Necessity Requirements 2026
Policy 0520 sits at the center of one of the most contested billing categories in oncology. Molecular diagnostic testing — tumor profiling, next-generation sequencing (NGS), proteomic panels, liquid biopsy, and companion diagnostic assays — generates significant reimbursement but also generates significant scrutiny. Cigna's coverage policy for these services has historically been restrictive, and modifications to Policy 0520 typically signal tighter criteria or newly defined experimental designations.
The real issue with this category is medical necessity documentation. Cigna requires that molecular and proteomic tests ordered for hematology and oncology patients meet specific clinical criteria before coverage applies. That means the ordering clinician's documentation needs to show why the test result will change patient management — not just that the test was ordered as part of a workup.
Prior authorization requirements for high-cost molecular panels are common under Cigna's framework for this policy. If your oncology practice orders multi-gene panels or comprehensive genomic profiling, confirm prior auth requirements are current as of April 11, 2026. A lapse in authorization alignment is one of the fastest paths to a claim denial on these services.
Cigna's coverage policy framework for molecular diagnostics also distinguishes between tests with established clinical utility and those still under evaluation. Tests with peer-reviewed evidence supporting their role in treatment selection for specific tumor types generally fare better. Tests ordered broadly — without a documented treatment decision tied to the result — face coverage challenges regardless of whether the test itself has technical approval.
The 0520 policy in the Cigna system applies broadly across hematologic malignancies and solid tumors. Covered indications have historically included tests that guide FDA-approved targeted therapy selection, tests that establish diagnosis in ambiguous hematologic presentations, and tests required for enrollment in certain clinical protocols. But the line between covered and experimental shifts with each policy modification — which is exactly why this April 11 update matters.
Cigna Molecular Diagnostic Testing Exclusions and Non-Covered Indications
Cigna has consistently designated certain molecular and proteomic testing categories as experimental, investigational, or unproven under Policy 0520. This is where claim denials concentrate.
Proteomics-based testing — using protein expression patterns rather than genomic data to guide treatment — has faced experimental designations across multiple payer policies, not just Cigna's. If your lab or practice bills proteomic profiling tests for tumor characterization, those claims carry elevated denial risk under this policy.
Multi-analyte assays with algorithmic analysis (MAAAs) occupy a gray zone. Some have achieved covered status based on specific oncology applications. Others remain non-covered pending additional clinical evidence. The distinction matters because MAAAs bill at price points that make a single denial costly.
Tumor profiling panels ordered for patients with no actionable therapy options, or ordered without documentation linking the result to a specific clinical decision, are a common source of non-coverage determinations. Cigna's medical necessity standard requires that the test result be reasonably expected to change management. Document that expectation explicitly in the chart — not just the order.
Repeat molecular testing on the same tumor without documented evidence of disease progression or a new clinical question is another exclusion pattern. If your practice bills serial NGS panels on the same patient, confirm the clinical rationale meets Cigna's criteria for each instance.
Coverage Indications at a Glance
Because the published policy data for this update does not include a specific code list or indication-by-indication breakdown, the table below reflects the general coverage framework Cigna applies under Policy 0520 based on the policy category and title. Confirm individual indication status against the full policy document before April 11, 2026.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Molecular testing to guide FDA-approved targeted therapy selection (solid tumors) | Covered when criteria met | Not specified in available data | Medical necessity documentation required; prior auth likely required for panel tests |
| Molecular testing for diagnosis of hematologic malignancies | Covered when criteria met | Not specified in available data | Must support diagnosis or treatment selection; document clinical rationale |
| Comprehensive genomic profiling (NGS panels) | Covered for select indications; experimental for others | Not specified in available data | Coverage varies by tumor type and clinical context; verify prior auth |
| Proteomic profiling for tumor characterization | Experimental / Not Covered | Not specified in available data | Cigna has historically designated proteomics-based testing as unproven |
| Multi-analyte assays with algorithmic analysis (MAAAs) | Mixed — indication-specific | Not specified in available data | Some covered; others experimental; review by specific assay |
| Repeat molecular testing without documented progression | Not Covered | Not specified in available data | Serial testing requires documented clinical rationale for each instance |
| Liquid biopsy for treatment selection | Covered for select indications | Not specified in available data | Rapidly evolving category; confirm current status under updated policy |
Cigna Molecular Diagnostic Testing Billing Guidelines and Action Items 2026
This is where the rubber meets the road. Here's what your billing team and your clinical documentation team need to do before April 11, 2026.
| # | Action Item |
|---|---|
| 1 | Pull your Cigna molecular diagnostic claims from the last 12 months. Identify every claim billed under tumor profiling, NGS, liquid biopsy, proteomic testing, and MAAA codes. Map your volume by indication. This tells you where your denial exposure concentrates under the updated policy. |
| 2 | Confirm prior authorization requirements for each test category before April 11. Contact your Cigna provider relations rep or check the Cigna provider portal directly. Prior auth requirements change when policies modify, and a claim denied for missing authorization is harder to appeal than one denied for medical necessity. |
| 3 | Audit your medical necessity documentation templates. Every molecular or proteomic test ordered for a Cigna patient needs a clear clinical rationale in the chart — specifically that the result will change patient management. If your oncologists are using generic order templates, update them now. The documentation needs to answer Cigna's coverage question before the claim is submitted. |
| 4 | Review your charge capture for any proteomic or MAAA tests. These categories carry the highest experimental designation risk. If you're billing these services to Cigna patients, loop in your compliance officer before the April 11 effective date to assess whether your current billing practice aligns with the updated policy. |
| 5 | Set up a pre-claim review process for high-cost molecular panels. For any panel billing above your practice's materiality threshold, build in a verification step: Is the indication covered under Policy 0520? Is prior auth in place? Is the medical necessity documentation complete? A denial on a $3,000 NGS panel costs more than the 10 minutes it takes to verify coverage upfront. |
| 6 | Update your denial management workflow for post-April 11 claims. If Cigna denies a molecular diagnostic claim after the effective date, the denial reason code will tell you whether it's a medical necessity issue, a prior auth issue, or an experimental designation. Each requires a different appeal strategy. Make sure your billing team knows the difference and routes appeals accordingly. |
| 7 | If you're not sure how this policy applies to your specific test mix, talk to your compliance officer before April 11. This is a complex, high-exposure category. The policy title covers a wide range of tests across hematology and oncology, and the updated criteria may affect different services in your portfolio differently. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Molecular and Proteomic Oncology Testing Under Policy 0520
The published policy data for this update does not include a specific list of CPT, HCPCS, or ICD-10 codes. This is not unusual for Cigna's molecular diagnostic policies — the category is broad, and applicable codes span multiple code sets.
Do not rely on assumed codes for billing decisions. Access the full Policy 0520 document directly through the Cigna provider portal or through the source link at app.payerpolicy.org to confirm the current code list effective April 11, 2026.
In the absence of published code data here, the relevant code categories for this policy type generally include:
- Molecular pathology codes (CPT 81xxx range) for single-gene and multi-gene analysis
- Genomic sequencing procedure codes (CPT 81410–81479 range) for NGS panels
- MAAA codes (CPT 81490–81599 range) for multi-analyte algorithmic assays
- Proprietary laboratory analyses (PLA) codes for specific branded assays
- Pathology and laboratory HCPCS codes where applicable
Confirm exact codes against the current policy before billing. Molecular diagnostic coding is one of the highest-risk areas for code-level mismatches between what you bill and what the policy covers.
Get the Full Picture for CPT 81410
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.